TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Enhancing Caregiver Support for Patients With Heart Failure
Brief Summary: Informal caregivers, assisted by health information technology may help to fill the gaps in VA care management of heart failure patients by enhancing support for patients' treatment adherence, behavior changes, and symptom monitoring.


Options:
A: Intervention Type: OTHER; Name: Peer Support; Assigned to Arm(s): N/A
B: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Behavioral: HITCM+CP | Arm Label: Arm 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: HITCM only | Intervention Type: BEHAVIORAL; Name: HITCM+CP; Assigned to Arm(s): Arm 1 | Intervention Type: BEHAVIORAL; Name: HITCM only; Assigned to Arm(s): Arm 2
C: Intervention Type: BEHAVIORAL; Name: Self-Management; Assigned to Arm(s): N/A | Intervention Type: OTHER; Name: attention control; Assigned to Arm(s): N/A
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Stepping Up to Health | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: Stepping Up to Health | Intervention Type: BEHAVIORAL; Name: Stepping Up to Health; Assigned to Arm(s): 1, 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Enhancing Caregiver Support for Patients With Heart Failure
Brief Summary: Informal caregivers, assisted by health information technology may help to fill the gaps in VA care management of heart failure patients by enhancing support for patients' treatment adherence, behavior changes, and symptom monitoring.


Options:
A: Arm Label: Intervention; Type: N/A; Interventions: Behavioral: Intervention | Arm Label: Usual Care; Type: N/A; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Intervention; Assigned to Arm(s): Intervention
B: Arm Label: Talking Rx; Type: EXPERIMENTAL; Interventions: Behavioral: Talking Rx | Arm Label: Usual Care, Prescriptions and Counselling; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Talking Rx; Assigned to Arm(s): Talking Rx
C: Arm Label: remote monitoring; Type: EXPERIMENTAL; Interventions: Device: heart failure remote patient monitoring system | Arm Label: control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: heart failure remote patient monitoring system; Assigned to Arm(s): remote monitoring
D: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Behavioral: HITCM+CP | Arm Label: Arm 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: HITCM only | Intervention Type: BEHAVIORAL; Name: HITCM+CP; Assigned to Arm(s): Arm 1 | Intervention Type: BEHAVIORAL; Name: HITCM only; Assigned to Arm(s): Arm 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Enhancing Caregiver Support for Patients With Heart Failure
Brief Summary: Informal caregivers, assisted by health information technology may help to fill the gaps in VA care management of heart failure patients by enhancing support for patients' treatment adherence, behavior changes, and symptom monitoring.


Options:
A: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Behavioral: HITCM+CP | Arm Label: Arm 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: HITCM only | Intervention Type: BEHAVIORAL; Name: HITCM+CP; Assigned to Arm(s): Arm 1 | Intervention Type: BEHAVIORAL; Name: HITCM only; Assigned to Arm(s): Arm 2
B: Arm Label: Check Yourself App With Feedback; Type: EXPERIMENTAL; Interventions: Behavioral: Check Yourself App with Feedback | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Check Yourself App with Feedback; Assigned to Arm(s): Check Yourself App With Feedback
C: Arm Label: Intervention Group; Type: EXPERIMENTAL; Interventions: Other: Loop | Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Loop; Assigned to Arm(s): Intervention Group
D: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Other: Intervention | Arm Label: Attention; Type: EXPERIMENTAL; Interventions: Other: Attention | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Other: Control | Intervention Type: OTHER; Name: Intervention; Assigned to Arm(s): Intervention | Intervention Type: OTHER; Name: Attention; Assigned to Arm(s): Attention | Intervention Type: OTHER; Name: Control; Assigned to Arm(s): Control

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Safety, Tolerability, and Pharmacokinetics of Multiple Doses of Staccato® Loxapine for Inhalation in Subjects on Chronic, Stable Antipsychotic Regimens
Brief Summary: The objectives of this trial are to assess the safety, tolerability, and pharmacokinetics of multiple inhaled doses of Staccato Loxapine.


Options:
A: Arm Label: sulpiride plus amisulpride; Type: EXPERIMENTAL; Interventions: Drug: full-dose amisulpride | Arm Label: full-dose amisulpride; Type: ACTIVE_COMPARATOR; Interventions: Drug: full-dose amisulpride | Intervention Type: DRUG; Name: full-dose amisulpride; Assigned to Arm(s): full-dose amisulpride, sulpiride plus amisulpride
B: Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: pimozide; Type: EXPERIMENTAL; Interventions: Drug: Pimozide | Intervention Type: DRUG; Name: Pimozide; Assigned to Arm(s): pimozide | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): placebo
C: Arm Label: Olanzapine or Placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: Amisulpride, Drug: Olanzapine and Amisulpride | Arm Label: Amisulpride or Placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: Olanzapine, Drug: Olanzapine and Amisulpride | Arm Label: Olanzapine and Amisulpride; Type: ACTIVE_COMPARATOR; Interventions: Drug: Olanzapine, Drug: Amisulpride | Intervention Type: DRUG; Name: Olanzapine; Assigned to Arm(s): Amisulpride or Placebo, Olanzapine and Amisulpride | Intervention Type: DRUG; Name: Amisulpride; Assigned to Arm(s): Olanzapine and Amisulpride, Olanzapine or Placebo | Intervention Type: DRUG; Name: Olanzapine and Amisulpride; Assigned to Arm(s): Amisulpride or Placebo, Olanzapine or Placebo
D: Arm Label: A - 10 mg loxapine q 4 h x 3 (30 mg total); Type: EXPERIMENTAL; Interventions: Drug: A - 10 mg loxapine q 4 h x 3 (30 mg total) | Arm Label: B - 10 mg x 1, 5 mg x 2 loxapine q 4 h (20 mg total); Type: EXPERIMENTAL; Interventions: Drug: B - 10 mg x 1, 5 mg x 2 loxapine q 4 h (20 mg total) | Arm Label: C - 5 mg loxapine q 4 h x 3 (15 mg total); Type: EXPERIMENTAL; Interventions: Drug: C - 5 mg loxapine q 4 h x 3 (15 mg total) | Arm Label: D - inhaled placebo q 4 h x 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: D - inhaled placebo q 4 h x 3 | Intervention Type: DRUG; Name: A - 10 mg loxapine q 4 h x 3 (30 mg total); Assigned to Arm(s): A - 10 mg loxapine q 4 h x 3 (30 mg total) | Intervention Type: DRUG; Name: B - 10 mg x 1, 5 mg x 2 loxapine q 4 h (20 mg total); Assigned to Arm(s): B - 10 mg x 1, 5 mg x 2 loxapine q 4 h (20 mg total) | Intervention Type: DRUG; Name: C - 5 mg loxapine q 4 h x 3 (15 mg total); Assigned to Arm(s): C - 5 mg loxapine q 4 h x 3 (15 mg total) | Intervention Type: DRUG; Name: D - inhaled placebo q 4 h x 3; Assigned to Arm(s): D - inhaled placebo q 4 h x 3

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Buprenorphine Maintenance vs. Detoxification in Prescription Opioid Dependence
Brief Summary: The aim of the study is to determine whether buprenorphine/naloxone maintenance versus detoxification using buprenorphine/naloxone, in prescription opioid dependent patients receiving primary care management and drug counseling in an office-based setting, leads to decreased illicit opioid use.


Options:
A: Arm Label: Buprenorphine/Nx; Type: EXPERIMENTAL; Interventions: Drug: Buprenorphine/naloxone | Arm Label: Methadone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methadone | Intervention Type: DRUG; Name: Buprenorphine/naloxone; Assigned to Arm(s): Buprenorphine/Nx | Intervention Type: DRUG; Name: Methadone; Assigned to Arm(s): Methadone
B: Arm Label: SC; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: SBIRT; Type: EXPERIMENTAL; Interventions: Behavioral: Brief Negotiation Interview (BNI) | Arm Label: SBI+Bup; Type: EXPERIMENTAL; Interventions: Behavioral: Brief Negotiation Interview (BNI), Drug: Buprenorphine Initiation | Intervention Type: BEHAVIORAL; Name: Brief Negotiation Interview (BNI); Assigned to Arm(s): SBI+Bup, SBIRT | Intervention Type: DRUG; Name: Buprenorphine Initiation; Assigned to Arm(s): SBI+Bup
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Behavioral: Buprenorphine/naloxone maintenance (Mtn) | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: Behavioral: Buprenorphine/naloxone detoxification (Dtx) | Intervention Type: BEHAVIORAL; Name: Behavioral: Buprenorphine/naloxone maintenance (Mtn); Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Behavioral: Buprenorphine/naloxone detoxification (Dtx); Assigned to Arm(s): 2
D: Arm Label: Methadone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methadone | Arm Label: Buprenorphine/naloxone; Type: EXPERIMENTAL; Interventions: Drug: Buprenorphine/naloxone | Intervention Type: DRUG; Name: Methadone; Assigned to Arm(s): Methadone | Intervention Type: DRUG; Name: Buprenorphine/naloxone; Assigned to Arm(s): Buprenorphine/naloxone

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Buprenorphine Maintenance vs. Detoxification in Prescription Opioid Dependence
Brief Summary: The aim of the study is to determine whether buprenorphine/naloxone maintenance versus detoxification using buprenorphine/naloxone, in prescription opioid dependent patients receiving primary care management and drug counseling in an office-based setting, leads to decreased illicit opioid use.


Options:
A: Arm Label: Buprenorphine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Buprenorphine, Drug: Vivitrol | Arm Label: Oral naltrexone; Type: ACTIVE_COMPARATOR; Interventions: Drug: oral naltrexone, Drug: Buprenorphine, Drug: Vivitrol | Intervention Type: DRUG; Name: oral naltrexone; Assigned to Arm(s): Oral naltrexone | Intervention Type: DRUG; Name: Buprenorphine; Assigned to Arm(s): Buprenorphine, Oral naltrexone | Intervention Type: DRUG; Name: Vivitrol; Assigned to Arm(s): Buprenorphine, Oral naltrexone
B: Arm Label: Active electroacupuncture; Type: ACTIVE_COMPARATOR; Interventions: Device: Electroacupuncture | Arm Label: Sham electroacupuncture; Type: SHAM_COMPARATOR; Interventions: Device: Electroacupuncture | Intervention Type: DEVICE; Name: Electroacupuncture; Assigned to Arm(s): Active electroacupuncture, Sham electroacupuncture
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Behavioral: Buprenorphine/naloxone maintenance (Mtn) | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: Behavioral: Buprenorphine/naloxone detoxification (Dtx) | Intervention Type: BEHAVIORAL; Name: Behavioral: Buprenorphine/naloxone maintenance (Mtn); Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Behavioral: Buprenorphine/naloxone detoxification (Dtx); Assigned to Arm(s): 2
D: Arm Label: Buprenorphine/Nx with EMM; Type: EXPERIMENTAL; Interventions: Behavioral: Enhanced Medical Management (EMM) of Prescription Opiate Abuse | Arm Label: Buprenorphine/Nx with SMM; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Standard Medical Management (SMM) of Prescription Opiate Abuse | Intervention Type: BEHAVIORAL; Name: Standard Medical Management (SMM) of Prescription Opiate Abuse; Assigned to Arm(s): Buprenorphine/Nx with SMM | Intervention Type: BEHAVIORAL; Name: Enhanced Medical Management (EMM) of Prescription Opiate Abuse; Assigned to Arm(s): Buprenorphine/Nx with EMM

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Longitudinal Assessment of Clinical Course and BIOmarkers in Severe Chronic AIRway Disease
Brief Summary: The aim of the project is to study pathogenetic mechanisms in severe asthma and compare those mechanisms in chronic obstructive pulmonary disease (COPD) in order to test the hypothesis that severe asthma and COPD develop into similar chronic degenerative changes.


Options:
A: Arm Label: steroid; Type: ACTIVE_COMPARATOR; Interventions: Drug: prednisolone | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: prednisolone | Intervention Type: DRUG; Name: prednisolone; Assigned to Arm(s): placebo, steroid
B: Arm Label: Fluticasone 44 mcg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fluticasone 44 mcg | Arm Label: Fluticasone 220 mcg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fluticasone 220 mcg | Intervention Type: DRUG; Name: Fluticasone 44 mcg; Assigned to Arm(s): Fluticasone 44 mcg | Intervention Type: DRUG; Name: Fluticasone 220 mcg; Assigned to Arm(s): Fluticasone 220 mcg
C: Arm Label: PARTICS; Type: ACTIVE_COMPARATOR; Interventions: Drug: PARTICS using QVAR | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: PARTICS using QVAR; Assigned to Arm(s): PARTICS
D: Arm Label: Sequence #1; Type: EXPERIMENTAL; Interventions: Drug: fluticasone propionate + montelukast, Drug: fluticasone propionate, Drug: fluticasone propionate + salmeterol | Arm Label: Sequence #2; Type: EXPERIMENTAL; Interventions: Drug: fluticasone propionate + montelukast, Drug: fluticasone propionate, Drug: fluticasone propionate + salmeterol | Arm Label: Sequence #3; Type: EXPERIMENTAL; Interventions: Drug: fluticasone propionate + montelukast, Drug: fluticasone propionate, Drug: fluticasone propionate + salmeterol | Arm Label: Sequence #4; Type: EXPERIMENTAL; Interventions: Drug: fluticasone propionate + montelukast, Drug: fluticasone propionate, Drug: fluticasone propionate + salmeterol | Arm Label: Sequence #5; Type: EXPERIMENTAL; Interventions: Drug: fluticasone propionate + montelukast, Drug: fluticasone propionate, Drug: fluticasone propionate + salmeterol | Arm Label: Sequence #6; Type: EXPERIMENTAL; Interventions: Drug: fluticasone propionate + montelukast, Drug: fluticasone propionate, Drug: fluticasone propionate + salmeterol | Intervention Type: DRUG; Name: fluticasone propionate + montelukast; Assigned to Arm(s): Sequence #1, Sequence #2, Sequence #3, Sequence #4, Sequence #5, Sequence #6 | Intervention Type: DRUG; Name: fluticasone propionate; Assigned to Arm(s): Sequence #1, Sequence #2, Sequence #3, Sequence #4, Sequence #5, Sequence #6 | Intervention Type: DRUG; Name: fluticasone propionate + salmeterol; Assigned to Arm(s): Sequence #1, Sequence #2, Sequence #3, Sequence #4, Sequence #5, Sequence #6

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Can a Behavioural Modifying Intervention Increase the Self-care and the Effect of the Diabetes Treatment in Chronically Ill Patients With Diabetes
Brief Summary: Diabetes is a common condition associated with increased morbidity and mortality. Non-pharmacological intervention strategies focusing on factors to improve self-management skills are considered an important part of the treatment in individuals with diabetes. Because of the increasing incidence in diabetes with costs (both physical, psychological and financial) for both patients and society it is important to investigate interventions that successfully promote self-care behaviour in patient with diabetes. Further research is needed to develop interventions effective in maintaining long-term glycemic control.

The aim of this project is to study the long-term effect of a motivational intervention program with an individual approach based on cognitive-behavioural strategies in chronically ill patients with diabetes. The effect will be evaluated on both physiological and psychosocial parameters including patient's experienced self-care competence.

The study will also provide an overview of what kind of non-pharmacological interventions that have been applied in relation to the treatment of type 2 diabetes and assess the effect of the various non-pharmacological interventions in randomised controlled trials.


Options:
A: Arm Label: Enhanced treatment as usual; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Enhanced treatment as usual plus adherence training | Arm Label: CBT-AD; Type: EXPERIMENTAL; Interventions: Behavioral: Enhanced treatment as usual plus CBT-AD | Intervention Type: BEHAVIORAL; Name: Enhanced treatment as usual plus adherence training; Assigned to Arm(s): Enhanced treatment as usual | Intervention Type: BEHAVIORAL; Name: Enhanced treatment as usual plus CBT-AD; Assigned to Arm(s): CBT-AD
B: Arm Label: Geriatric Diabetes Team Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Behavioral | Arm Label: Atention Control Arm; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Behavioral; Assigned to Arm(s): Geriatric Diabetes Team Intervention
C: Intervention Type: BEHAVIORAL; Name: An individual motivational intervention program to promote and maintain self-care behaviour; Assigned to Arm(s): N/A
D: Arm Label: self-guided weight loss maintenance; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: DVD group; Type: EXPERIMENTAL; Interventions: Behavioral: PILI 'Ohana 18-month weight loss maintenance | Arm Label: face-to-face group; Type: EXPERIMENTAL; Interventions: Behavioral: PILI 'Ohana 18-month weight loss maintenance | Intervention Type: BEHAVIORAL; Name: PILI 'Ohana 18-month weight loss maintenance; Assigned to Arm(s): DVD group, face-to-face group

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Randomized, Multi-Center, Double-Blind, Parallel-Group, Placebo-Controlled Study of NRP104 in Children Aged 6-12 Years With Attention Deficit Hyperactivity Disorder
Brief Summary: This study is designed to assess efficacy and safety of NRP-104 administered as a daily dose of 30mg, 50mg or 70mg compared to placebo in the treatment of children aged 6-12 years with ADHD.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: NRP104 | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: NRP104 | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: NRp104 | Arm Label: 4; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: NRP104; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: NRP104; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: NRp104; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 4
B: Arm Label: Adderall Extended Release First; Type: EXPERIMENTAL; Interventions: Drug: Adderall ® Immediate Release, Drug: Adderall XR ® | Arm Label: Adderall Immediate Release First; Type: EXPERIMENTAL; Interventions: Drug: Adderall ® Immediate Release, Drug: Adderall XR ® | Intervention Type: DRUG; Name: Adderall ® Immediate Release; Assigned to Arm(s): Adderall Extended Release First, Adderall Immediate Release First | Intervention Type: DRUG; Name: Adderall XR ®; Assigned to Arm(s): Adderall Extended Release First, Adderall Immediate Release First
C: Arm Label: LDX Treatment; Type: EXPERIMENTAL; Interventions: Drug: LDX Treatment | Intervention Type: DRUG; Name: LDX Treatment; Assigned to Arm(s): LDX Treatment
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Adderall-XR 60 mg; Type: EXPERIMENTAL; Interventions: Drug: Adderall-XR | Arm Label: Adderall-XR 80 mg; Type: EXPERIMENTAL; Interventions: Drug: Adderall-XR | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Adderall-XR; Assigned to Arm(s): Adderall-XR 60 mg | Intervention Type: DRUG; Name: Adderall-XR; Assigned to Arm(s): Adderall-XR 80 mg

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluation of CHAM JAM (Previously Known as the Moving Smart) Intervention in Increasing Physical Activity in Bronx Elementary School Students
Brief Summary: The purpose of this study is to determine if the "Moving Smart" program, a daily 10-minute classroom-based exercise program, increases physical activity levels during the school day in Bronx elementary school students.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Teacher-Delivered Weight Control Intervention | Arm Label: 2; Type: OTHER; Interventions: Behavioral: Teacher-Delivered General Health Intervention | Intervention Type: BEHAVIORAL; Name: Teacher-Delivered Weight Control Intervention; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Teacher-Delivered General Health Intervention; Assigned to Arm(s): 2
B: Arm Label: intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Training, Behavioral: Individual level, Behavioral: Organizational level | Arm Label: no intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Training; Assigned to Arm(s): intervention | Intervention Type: BEHAVIORAL; Name: Individual level; Assigned to Arm(s): intervention | Intervention Type: BEHAVIORAL; Name: Organizational level; Assigned to Arm(s): intervention
C: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Other: CHAM JAM | Arm Label: Wait-Listed Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: CHAM JAM; Assigned to Arm(s): Intervention
D: Arm Label: A+PAAC; Type: EXPERIMENTAL; Interventions: Behavioral: A+PAAC | Arm Label: CON; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: CON | Intervention Type: BEHAVIORAL; Name: A+PAAC; Assigned to Arm(s): A+PAAC | Intervention Type: BEHAVIORAL; Name: CON; Assigned to Arm(s): CON

Answer: C